Mission:

To protect, promote & improve the health of all people in Florida through integrated state, county & community efforts.



Scott A. Rivkees, MD

State Surgeon General

Vision: To be the Healthiest State in the Nation

Important Updates Regarding the Distribution of COVID-19 Therapeutics [Monoclonal Antibodies]

February 22, 2021

The distribution of COVID-19 therapeutics will transition from State allocations to a direct ordering system. Starting with the next distribution cycle on <u>3/3/21</u>, COVID-19 therapeutic products will be available for direct ordering from Amerisource Bergen.

Any facility in a state that can administer these products will be able to order directly from Amerisource Bergen. The state of Florida will no longer play a role in allocating or distributing COVID-19 therapeutics to facilities. The cost of these products is covered by the Federal Government and is provided at no cost to facilities. Facilities that have been receiving these products through the SPEED Program must also transition to direct ordering.

The U.S. Department of Health and Human Services (HHS) Therapeutics Team and/or Amerisource Bergen will send information on this change to sites already utilizing the direct order system before the end of this current cycle. The direct ordering process will still allow sites to gather additional supply and receive next-day orders as necessary.

Additional updates will be provided by HHS or Amerisource Bergen when the combination bamlanivimab/etesivimab product will be available or when casirivimab/Imdevimab will become available again.

New sites seeking access to COVID-19 therapeutic products can currently access registration through the link below.

https://app.smartsheet.com/b/form/255d164d67834793b4ab549e160941e8

For information on direct ordering, please visit the link below. https://www.phe.gov/emergency/events/COVID19/investigation-
MCM/Documents/Overview%20of%20direct%20order%20process%20Fact%20Sheet-508.pdf

